⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Señorita Broadens Portfolio With 1777, the Brand’s First Non-Alcoholic THC Spirit
globenewswire.com
RYTM
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
globenewswire.com
RYTM
Introducing Peanut Buddah Cups, A New and Nutty THC Treat From incredibles
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Changes to Board of Directors
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
globenewswire.com
RYTM